German cytometry startup Zellkraftwerk has begun offering researchers early access to its Chipcytometry platform in advance of a planned fall sales release for the device.

The company launched the platform this month as a biomarker development service aimed at academic researchers and pharmaceutical firms, Christian Hennig, Zellkraftwerk's co-founder and CEO, told ProteoMonitor. It intends to begin sales of the instrument itself in September, he added.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.